- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07712575
A Study of V132 in Healthy Older Participants (V132-001)
A Phase 1, Randomized, Double-Blind, Comparator-Controlled Dose-Escalation Study to Evaluate the Safety, Tolerability, and Immunogenicity of V132 in Healthy Older Participants
The goal of this study is to learn about the safety and immune response to the V132 vaccine in healthy older adults.
Studieöversikt
Status
Betingelser
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Toll Free Number
- Telefonnummer: 1-888-577-8839
- E-post: Trialsites@msd.com
Studieorter
-
-
California
-
Anaheim, California, Förenta staterna, 92801
- Rekrytering
- Anaheim Clinical Trials ( Site 0006)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 714-774-7777
-
-
Florida
-
Hallandale, Florida, Förenta staterna, 33009
- Rekrytering
- Velocity Clinical Research, Hallandale Beach ( Site 0003)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 954-455-5757
-
Hollywood, Florida, Förenta staterna, 33024
- Rekrytering
- Research Centers of America ( Hollywood ) ( Site 0009)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 954-990-7649
-
South Miami, Florida, Förenta staterna, 33143
- Rekrytering
- QPS-MRA, LLC-Early Phase ( Site 0001)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 305-722-0970
-
-
Missouri
-
Springfield, Missouri, Förenta staterna, 65802
- Rekrytering
- Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0002)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 417-831-2048
-
-
Nebraska
-
Lincoln, Nebraska, Förenta staterna, 68510
- Rekrytering
- Velocity Clinical Research Lincoln ( Site 0007)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 531-530-2800
-
Omaha, Nebraska, Förenta staterna, 68134
- Rekrytering
- Velocity Clinical Research, Omaha ( Site 0008)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 402-933-6500
-
-
Ohio
-
Columbus, Ohio, Förenta staterna, 43215
- Rekrytering
- Remington-Davis, Inc. ( Site 0005)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 614-487-2560
-
-
Rhode Island
-
East Greenwich, Rhode Island, Förenta staterna, 02818
- Rekrytering
- Velocity Clinical Research, Providence ( Site 0010)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 401-739-9350
-
-
Texas
-
League City, Texas, Förenta staterna, 77573
- Rekrytering
- University of Texas Medical Branch ( Site 0004)
-
Kontakt:
- Study Coordinator
- Telefonnummer: 832-340-2313
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
The key inclusion criteria include but are not limited to the following:
- Is in good health
- Has body mass index (BMI) within 18.0 to 35.0 kg/m^2 (inclusive)
Exclusion Criteria:
The key exclusion criteria include but are not limited to the following:
- Has a history of invasive pneumococcal disease or known history of other culture-positive pneumococcal disease within 3 years prior to receiving study vaccination
- Has received a pneumococcal polysaccharide vaccine in the previous 10 years, has received any pneumococcal conjugate vaccine at any time prior to this study
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part 1: Dose Escalation
Participants will receive single intramuscular (IM) doses of a V132 formulation or comparator regimen at varying dose levels. |
Experimental Experimental Experimental Active Comparator Active Comparator |
|
Experimentell: Part 2: Dose Expansion
Participants will receive single IM doses of a V132 formulation or comparator regimen. Doses will be determined based on review of Part 1 data and will not exceed maximum dose level assessed in Part 1. |
Experimental Experimental Experimental Active Comparator Active Comparator |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Participants with Immediate Reactions Occurring Within 30 Minutes After Any Vaccination
Tidsram: Up to approximately 30 minutes post vaccination
|
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The percentage of participants with immediate reactions occurring within 30 minutes after any vaccination will be reported. |
Up to approximately 30 minutes post vaccination
|
|
Percentage of Participants with a Solicited Injection-site Adverse Event
Tidsram: Up to approximately 7 days post vaccination
|
An AE is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The solicited injection-site AEs assessed are redness/erythema, swelling, and tenderness/pain. The percentage of participants with a solicited injection-site adverse event will be reported. |
Up to approximately 7 days post vaccination
|
|
Percentage of Participants with a Solicited Systemic Adverse Event
Tidsram: Up to approximately 7 days post vaccination
|
An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The solicited systemic AEs assessed are muscle pain/myalgia, joint pain/arthralgia, headache, and tiredness/fatigue. The percentage of participants with a solicited systemic adverse event will be reported. |
Up to approximately 7 days post vaccination
|
|
Percentage of Participants With at Least 1 Unsolicited Adverse Event
Tidsram: Up to approximately 28 days post vaccination
|
An unsolicited AE is an AE that was not solicited using a vaccination report card (VRC) and that is communicated by a participant (or their legally acceptable representative, if applicable). Unsolicited AEs include serious and nonserious AEs. The percentage of participants with at least 1 unsolicited adverse event will be reported. |
Up to approximately 28 days post vaccination
|
|
Percentage of Participants with a Serious Adverse Event
Tidsram: Up to approximately 12 months post vaccination
|
A serious adverse event (SAE) is an AE that results in death, is life threatening, results in a persistent or significant disability or incapacity, results in or prolongs an existing hospitalization, is a congenital anomaly or birth defect, is a cancer, is an overdose, or is another important medical event. The percentage of participants that experienced 1 or more SAEs will be reported. |
Up to approximately 12 months post vaccination
|
|
Percentage of Participants With at Least 1 Medically Attended Adverse Event
Tidsram: Up to approximately 12 months post vaccination
|
A medically attended adverse event (MAAE) is an AE in which medical attention is received during an unscheduled, non-routine outpatient visit, such as an emergency room visit, office visit, or an urgent care visit with any medical personnel for any reason. The percentage of participants with at least 1 MAAE will be reported. |
Up to approximately 12 months post vaccination
|
|
Percentage of Participants Who Experienced an Adverse Event of Clinical Interest
Tidsram: Up to approximately 12 months post vaccination
|
Events of clinical interest (ECIs) are defined as an overdose of Sponsor's product, drug-induced liver injury events, or potential immune-mediated diseases (pIMDs). The percentage of participants who experienced an adverse event of clinical interest will be reported. |
Up to approximately 12 months post vaccination
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Geometric Mean Titer of Serotype-specific Opsonophagocytic Activity (OPA)
Tidsram: Up to approximately 28 days post vaccination
|
Opsonophagocytic activity (OPA) for serotypes in V132 formulations will be determined using a multiplexed opsonophagocytic assay (MOPA). Geometric Mean Titer (GMT) of serotype-specific OPA will be reported. |
Up to approximately 28 days post vaccination
|
|
Geometric Mean Fold Rise from Baseline of Serotype-specific OPA
Tidsram: Baseline (pre-vaccination) and 28 days post vaccination
|
The Geometric Mean Fold Rise (GMFR) from baseline in serotype-specific OPA GMTs for serotypes in V132 formulations will be determined using a multiplexed opsonophagocytic assay (MOPA). GMFR is defined as the geometric mean of the ratio of concentration at Day 28 post vaccination divided by concentration at baseline. |
Baseline (pre-vaccination) and 28 days post vaccination
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Medical Director, Merck Sharp & Dohme LLC
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Andra studie-ID-nummer
- V132-001
- V132-001 (Annan identifierare: MSD)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .